These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37094467)
1. bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer. Fan Y; Liu Y; Wang L; Cai Y; Cao W; Sun W; Zou X; Li B; Zhang Z; Cai S; Chuai S; Han Y; Pan X; Huang D EBioMedicine; 2023 May; 91():104564. PubMed ID: 37094467 [TBL] [Abstract][Full Text] [Related]
2. Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer. Zhou J; Bao M; Gao G; Cai Y; Wu L; Lei L; Zhao J; Ji X; Huang Y; Su C BMC Med; 2022 Jul; 20(1):256. PubMed ID: 35902848 [TBL] [Abstract][Full Text] [Related]
3. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553 [TBL] [Abstract][Full Text] [Related]
4. Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. Wang Z; Duan J; Wang G; Zhao J; Xu J; Han J; Zhao Z; Zhao J; Zhu B; Zhuo M; Sun J; Bai H; Wan R; Wang X; Fei K; Wang S; Zhao X; Zhang Y; Huang M; Huang D; Qi C; Gao C; Bai Y; Dong H; Xiong L; Tian Y; Wang D; Xu C; Wang W; Li J; Hu X; Cai S; Wang J J Thorac Oncol; 2020 Apr; 15(4):556-567. PubMed ID: 31843683 [TBL] [Abstract][Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
6. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. Ba H; Liu L; Peng Q; Chen J; Zhu YD BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004 [TBL] [Abstract][Full Text] [Related]
7. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001 [TBL] [Abstract][Full Text] [Related]
8. ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. Nie W; Wang ZJ; Zhang K; Li B; Cai YR; Wen FC; Zhang D; Bai YZ; Zhang XY; Wang SY; Cheng L; Zhong H; Liu L; Wang J; Han BH BMC Med; 2022 May; 20(1):170. PubMed ID: 35509036 [TBL] [Abstract][Full Text] [Related]
9. Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Thompson JC; Hwang WT; Davis C; Deshpande C; Jeffries S; Rajpurohit Y; Krishna V; Smirnov D; Verona R; Lorenzi MV; Langer CJ; Albelda SM Lung Cancer; 2020 Jan; 139():1-8. PubMed ID: 31683225 [TBL] [Abstract][Full Text] [Related]
10. Development and validation of a blood-based genomic mutation signature to predict the clinical outcomes of atezolizumab therapy in NSCLC. Liu M; Xia S; Zhang X; Zhang B; Yan L; Yang M; Ren Y; Guo H; Zhao J Lung Cancer; 2022 Aug; 170():148-155. PubMed ID: 35792434 [TBL] [Abstract][Full Text] [Related]
11. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Chen X; Fang L; Zhu Y; Bao Z; Wang Q; Liu R; Sun W; Du H; Lin J; Yu B; Chen S; Zhou J; Zhou J Cancer Immunol Immunother; 2021 Dec; 70(12):3513-3524. PubMed ID: 33899131 [TBL] [Abstract][Full Text] [Related]
12. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693 [TBL] [Abstract][Full Text] [Related]
13. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L J Immunother Cancer; 2019 Apr; 7(1):98. PubMed ID: 30944026 [TBL] [Abstract][Full Text] [Related]
14. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954 [TBL] [Abstract][Full Text] [Related]
15. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer. Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896 [TBL] [Abstract][Full Text] [Related]
16. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer. Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077 [TBL] [Abstract][Full Text] [Related]
18. Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with Metro G; Baglivo S; Bellezza G; Mandarano M; Gili A; Marchetti G; Toraldo M; Molica C; Reda MS; Tofanetti FR; Siggillino A; Prosperi E; Giglietti A; Di Girolamo B; Garaffa M; Marasciulo F; Minotti V; Gunnellini M; Guida A; Sassi M; Sidoni A; Roila F; Ludovini V Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33946594 [TBL] [Abstract][Full Text] [Related]
19. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586 [TBL] [Abstract][Full Text] [Related]
20. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis. Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]